Abstracts tagged "Raynaud’s phenomenon"

Abstract Number: 2970 • 2015 ACR/ARHP Annual Meeting
Primary Care Assessment of Capillaroscopy Abnormalities in Patients with Raynaud’s Phenomenon
Rebecca Overbury¹, Maureen Murtaugh², Aryeh Fischer³ and Tracy M. Frech⁴, ¹Internal Medicine and Pediatrics, University of Utah, Salt Lake City, UT, ²Internal Medicine-Division of Epidemiology, University of Utah School of Medicine, SLC, UT, ³University of Colorado School of Medicine, Aurora, CO, ⁴Div of Rheumatology, University of Utah Medical Ctr, Salt Lake City, UT
Background/Purpose: Raynaud’s phenomenon is a clinical symptom that can commonly present to a primary care provider or generalist. Proper identification of an underlying connective tissue…
Abstract Number: 2977 • 2015 ACR/ARHP Annual Meeting
A Meta-Analysis of Phosphodiesterase 5 Inhibitors for the Treatment of Raynaud’s Phenomenon
Janet E. Pope¹, Fadumo Rirash², Paul Tingey³, Sarah Harding⁴, Lara J. Maxwell⁵, Jordi Pardo⁶, Elizabeth Ghogomu⁷, Peter Tugwell⁸ and George A. Wells⁹, ¹University of Western Ontario, London, ON, Canada, ²Medicine/Rheumatology, University of Western Ontario, London, ON, Canada, ³Faculty of Medicine, University of Queensland, Brisbane, Australia, ⁴ERLanger, ERLanger, KY, ⁵Centre for Global Health, Institute of Population Health, University of Ottawa, Ottawa, ON, Canada, ⁶University of Ottawa, Ottawa, ON, Canada, ⁷University of Ottawa, Cochrane Musculoskeletal Group, Ottawa, ON, Canada, ⁸Center For Global Health, Institute of Population Hlth, Ottawa, ON, Canada, ⁹Cardiovascular Research Reference Centre, University of Ottawa Heart Institute, Ottawa, ON, Canada
Background/Purpose: To assess the benefits and harms of phosphodiesterase 5 inhibitors (PDE5) for the treatment of Raynaud's phenomenon (RP).Methods: The Cochrane library, MEDLINE, EMBASE and Clinicaltrials.gov…
Abstract Number: 2982 • 2015 ACR/ARHP Annual Meeting
Blood Perfusion in Different Skin Areas of Hands in Primary Raynaud’s Phenomenon and Systemic Sclerosis Patients
Alberto Sulli¹, Barbara Ruaro¹, Amelia Chiara Trombetta¹, Vanessa Smith², Carmen Pizzorni¹, Sabrina Paolino¹ and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy, ²Department of Rheumatology, Ghent University Hospital, Ghent University, Ghent, Belgium
Background/Purpose: Peripheral blood perfusion is reduced in patients affected by both primary (PRP) or secondary Raynaud’s phenomenon (SRP) (1-2). The objective of this study was…
Abstract Number: 3007 • 2015 ACR/ARHP Annual Meeting
Cold Receptor Expression and Function in Human Dermal Fibroblast: Possible Role in the Pathogenesis of Scleroderma Fibrosis
Yongqing Wang¹, John Sun¹, Shadia Nada², Nezam Altorok³ and Bashar Kahaleh⁴, ¹The University of Toledo, Toledo, OH, ²Internal Medicine, Divison of Rheumatology, The University of Toledo, Toledo, OH, ³Internal Medicine, Division of Rheumatology, The University of Toledo, Toledo, OH, ⁴Medicine/Rheumatology, The University of Toledo, Toledo, OH
Background/Purpose: Enhanced cold sensitivity is an early and consistent phenomenon in scleroderma (SSc). We previously demonstrated increased expression of the transient receptor potential melastatine 8…
Abstract Number: 638 • 2015 ACR/ARHP Annual Meeting
Assessment of Myocardial Abnormalities in Primary Sjögren Syndrome Using a Comprehensive Cardiac Magnetic Resonance Approach
Natsumi Ikumi¹, Hitomi Kobayashi², Yasuyuki Kobayashi³, Hirotake Inomata⁴, Yosuke Nagasawa⁴, Kaita Sugiyama⁴, Hiromi Karasawa¹, Takamasa Nozaki⁴, Hidetaka Shiraiwa⁴, Mitsuhiro Iwata², Noboru Kitamura⁵, Yoshihiro Matsukawa¹ and Masami Takei², ¹Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ³Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, ⁴Nihon University School of Medicine, Tokyo, Japan, ⁵NIhon University School of Medicine, Tokyo, Japan
Background/Purpose: Primary Sjögren syndrome (pSS) shares many clinical, inflammatory, and immunological features with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). SLE and RA are…
Abstract Number: 822 • 2015 ACR/ARHP Annual Meeting
Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial
Sei-ichiro Motegi¹, Kazuya Yamada¹, Sayaka Toki¹, Akihiko Uchiyama¹, Tetsuya Nakamura² and Osamu Ishikawa¹, ¹Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan, ²Clinical Investigation and Research Unit, Gunma University Graduate School of Medicine, Gunma, Japan
Background/Purpose: Systemic scleroderma (SSc) is a generalized connective tissue disease characterized by fibrosis of the skin and internal organs, vascular dysfunction and immune disorder. Patients…
Abstract Number: 3004 • 2014 ACR/ARHP Annual Meeting
Autoantibody-Mediated Raynaud’s Phenomenon: Animal Model and Human Disease
Dana P. Ascherman^1,2, Yunjuan Zang³, Laisel Martinez⁴, Judith Pignac-Kobinger⁵, Irina Fernandez³ and Eric L. Greidinger^3,4, ¹Medicine/Rheumatology, University of Miami, Miami, FL, ²Rheumatology, Miami VAMC, Miami, FL, ³Rheumatology, University of Miami, Miami, FL, ⁴Miami VAMC, Miami, FL, ⁵University of Miami, Miami, FL
Background/Purpose: Raynaud’s Phenomenon (RP) is frequently seen in autoimmune conditions, but an autoimmune basis for RP has not been established. Methods: Sera derived from anti-RNP+…
Abstract Number: 1930 • 2014 ACR/ARHP Annual Meeting
The Value of Repeated Nailfold Capillaroscopy in Raynaud’s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands
B. de Boer¹, J. Meijs¹, J. van Aken², T.W.J. Huizinga¹, A.a. Schouffoer³ and J.K. de Vries-Bouwstra⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Spaarne Ziekenhuis, Hoofddorp, Netherlands, ³Rheumatology, Haga Hospital, The Hague, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose Nailfold capillaroscopy is an important tool to differentiate primary Raynaud's phenomenon (PRP) from secondary Raynaud's phenomenon (SRP). Based on possible transition from PRP to…
Abstract Number: 1927 • 2014 ACR/ARHP Annual Meeting
A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil
Ami A. Shah¹, Elena Schiopu², Soumya Chatterjee³, Mary Ellen Csuka⁴, Tracy Frech⁵, Avram Goldberg⁶, Robert F. Spiera⁷, Stanford L. Peng⁸ and Virginia D. Steen⁹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, University of Michigan, Ann Arbor, MI, ³Rheumatic and Immunologic Ds, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ⁵Div of Rheumatology, University of Utah, Salt Lake City, UT, ⁶Div of Rheumatology, North Shore-LIJ Health System, Great Neck, NY, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Benaroya Research Institute/Virginia Mason, Seattle, WA, ⁹Department of Rheumatology, Georgetown University Medical Center, Washington, DC
Background/Purpose Ischemic digital ulcers (DU) occur in over 40% of systemic sclerosis (SSc) patients. Treprostinil diolamine, a newer prostacyclin analog that has been developed for…
Abstract Number: 1683 • 2014 ACR/ARHP Annual Meeting
Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon
Lucía Ruiz Gutiérrez¹, Ana Pérez Gómez¹, Nuria Valdeolivas Casillas², Henry Moruno Cruz¹, Eduardo Cuende Quintana¹, Ana Sánchez Atrio¹, Ana Turrión Nieves¹, Atusa Movasat¹, Cristina Bohórquez Heras¹, Fernando Albarrán Hernández¹, Maria Liz Romero Bogado¹, Susana Medina Montalvo² and Melchor Álvarez de Mon¹, ¹Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, ²Hospital Príncipe de Asturias, Dermatology department, Alcalá de Henares, Madrid, Spain
Background/Purpose Raynaud's phenomenon (RP) is characterized by transient episodes of vasoconstriction of the arteries and arterioles of the extremities in response to cold or emotional…
Abstract Number: 1699 • 2014 ACR/ARHP Annual Meeting
Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud’s Phenomenon
John D. Pauling^1,2, Daniel Moreno-Martinez³, Fiona Wilkinson⁴, Ben Parker^5,6, Jacqueline A. Shipley¹, Darren Hart¹, Neil J McHugh^1,2 and Yvonne Alexander³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ³Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴School of Healthcare Science, Manchester Metropolitan University, Manchester, United Kingdom, ⁵Institute of Inflammation and Repair School of Translation Medicine The University of Manchester, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ⁶Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom
Background/Purpose Microparticles (MPs) are membrane-bound vesicles derived from vascular and intravascular cells such as endothelial cells (EMPs) and platelets (PMPs). MPs form during cell activation…
Abstract Number: 1701 • 2014 ACR/ARHP Annual Meeting
Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry
Florenzo Iannone, Cinzia Rotondo, Mariangela Nivuori, Emanuela Praino, Laura Coladonato, Michele Covelli and Giovanni Lapadula, DIM, Rheumatology Unit, Bari, Italy
Background/Purpose Iloprost is a milestone in the treatment of Raynaud’s Phenomenon (RP). However, it has transient hemodynamic effects due to a very short half-time, thereby…
Abstract Number: 1702 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?
Anjali Shetty¹, Suncica Volkov¹, Claudia Vergara² and William Swedler³, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²Rheumatology, University of Illinois Chicago, Chicago, IL, ³Section of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by collagen deposition and vascular changes of the skin and internal organs, leading ultimately to fibrosis. …
Abstract Number: 1680 • 2014 ACR/ARHP Annual Meeting
an Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud’s Phenomenon
Sampath Manickam¹, Elie Donath², Sandeep Dayanand³ and Jonathan Greer⁴, ¹University of Miami Palm Beach Internal Medicine, West Palm Beach, FL, ²Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ³University of Miami Palm Beach Internal medicine, West palm beach, FL, ⁴Arthritis & Rheumatology Associates, Boynton Beach, FL
An Indirect Comparisons Analysis of Medications used for treatment of Raynaud’s phenomenonBackground/Purpose: There are several pharmacological treatments used for treatment of Raynaud’s phenomenon: calcium channel…
Abstract Number: 737 • 2014 ACR/ARHP Annual Meeting
Reliability of Nailfold Capillary Density Measurement As a Possible Outcome Measure for Systemic Sclerosis-Related Microangiopathy
Graham Dinsdale¹, Tonia Moore², Joanne Manning², Andrea Murray¹, Michael Berks³, Philip Tresadern³, Chris Taylor³, Neil O'Leary⁴, Chris Roberts⁴, John Allen⁵, Marina Anderson⁶, Maurizio Cutolo⁷, Roger Hesselstrand⁸, Kevin Howell⁹, Paula Pyrkotsch⁶, Francesca Ravera⁷, Vanessa Smith¹⁰, Alberto Sulli⁷, Marie Wildt⁸ and Ariane Herrick¹, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Salford Royal Hospital NHS Foundation Trust, Salford, United Kingdom, ³Centre for Imaging Sciences, University of Manchester, Institute of Population Health, Manchester, United Kingdom, ⁴Centre for Biostatistics, Institute of Population Health, University of Manchester, Manchester, United Kingdom, ⁵Regional Medical Physics Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom, ⁶Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom, ⁷Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁸Rheumatology, Lund University, Lund, Sweden, ⁹Institute of Immunity and Transplantation, University College London, Royal Free Campus, London, United Kingdom, ¹⁰Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
Background/Purpose Nailfold videocapillaroscopy allows non-invasive assessment of the microcirculation. Image annotation software allows tracking of changes over time; a potential outcome measure for systemic sclerosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].